CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

STAT News
Original article

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

PartnershipPositive
AI Analysis

Summary

Oak Hill Bio, backed by RA Capital and other investors, has been founded to develop an Angelman syndrome treatment, positioning itself as a competitor to Ultragenyx and Ionis in the rare brain disease space.

Importance:5/10
Sentiment:
0.30
rare diseaseAngelman syndromefundingcompetitive landscape
Related Companies

Read the original article

Published by STAT News on July 27, 2026 12:00 PM

Read Original